chr17-64546301-A-C
Position:
Variant summary
Our verdict is Likely benign. Variant got -4 ACMG points: 0P and 4B. BS2
The NM_022739.4(SMURF2):āc.2109T>Gā(p.Ile703Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000285 in 1,613,962 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Uncertain significance (ā ).
Frequency
Genomes: š 0.000053 ( 0 hom., cov: 32)
Exomes š: 0.000026 ( 0 hom. )
Consequence
SMURF2
NM_022739.4 missense
NM_022739.4 missense
Scores
2
4
13
Clinical Significance
Conservation
PhyloP100: -0.524
Genes affected
SMURF2 (HGNC:16809): (SMAD specific E3 ubiquitin protein ligase 2) Enables SMAD binding activity; identical protein binding activity; and ubiquitin-protein transferase activity. Involved in negative regulation of transforming growth factor beta receptor signaling pathway; positive regulation of trophoblast cell migration; and ubiquitin-dependent SMAD protein catabolic process. Located in nuclear speck. Part of ubiquitin ligase complex. [provided by Alliance of Genome Resources, Apr 2022]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Likely_benign. Variant got -4 ACMG points.
BS2
High AC in GnomAd4 at 8 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
SMURF2 | NM_022739.4 | c.2109T>G | p.Ile703Met | missense_variant | 18/19 | ENST00000262435.14 | NP_073576.1 | |
SMURF2 | XM_047436546.1 | c.2115T>G | p.Ile705Met | missense_variant | 18/19 | XP_047292502.1 | ||
SMURF2 | XM_005257585.4 | c.2070T>G | p.Ile690Met | missense_variant | 17/18 | XP_005257642.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
SMURF2 | ENST00000262435.14 | c.2109T>G | p.Ile703Met | missense_variant | 18/19 | 1 | NM_022739.4 | ENSP00000262435 | P1 | |
SMURF2 | ENST00000578386.5 | c.*1931T>G | 3_prime_UTR_variant, NMD_transcript_variant | 18/19 | 1 | ENSP00000464432 | ||||
SMURF2 | ENST00000582081.5 | c.*2016T>G | 3_prime_UTR_variant, NMD_transcript_variant | 18/19 | 5 | ENSP00000463531 |
Frequencies
GnomAD3 genomes AF: 0.0000526 AC: 8AN: 152224Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
8
AN:
152224
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000318 AC: 8AN: 251300Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135816
GnomAD3 exomes
AF:
AC:
8
AN:
251300
Hom.:
AF XY:
AC XY:
2
AN XY:
135816
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000260 AC: 38AN: 1461738Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727158
GnomAD4 exome
AF:
AC:
38
AN:
1461738
Hom.:
Cov.:
31
AF XY:
AC XY:
13
AN XY:
727158
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000526 AC: 8AN: 152224Hom.: 0 Cov.: 32 AF XY: 0.0000807 AC XY: 6AN XY: 74356
GnomAD4 genome
AF:
AC:
8
AN:
152224
Hom.:
Cov.:
32
AF XY:
AC XY:
6
AN XY:
74356
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
2
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | May 15, 2023 | The c.2109T>G (p.I703M) alteration is located in exon 18 (coding exon 18) of the SMURF2 gene. This alteration results from a T to G substitution at nucleotide position 2109, causing the isoleucine (I) at amino acid position 703 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
LIST_S2
Pathogenic
D
M_CAP
Benign
D
MetaRNN
Uncertain
D
MetaSVM
Benign
T
MutationAssessor
Benign
L
MutationTaster
Benign
D
PrimateAI
Pathogenic
D
PROVEAN
Benign
N
REVEL
Uncertain
Sift
Benign
T
Sift4G
Benign
T
Polyphen
D
Vest4
MutPred
Gain of catalytic residue at I703 (P = 0.0278);
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at